

To: Elizabeth Holmes[eholmes@theranos.com]
From: Daniel Edlin
Sent: Thur 8/22/2013 1:13:06 AM
Importance: Normal
Subject: FW: updates
Received: Thur 8/22/2013 1:13:07 AM

Hi Elizabeth – wanted to bring your attention to the below with regards to priorities of ELISA team and assay development for porcine assays.

Please let me know if these priorities should be shifted at all.

Thanks,
Dan

From: Sharada Sivaraman
Sent: Wednesday, August 21, 2013 8:52 AM
To: Suraj Saksena; Daniel Edlin
Cc: Surekha Gangakhedkar
Subject: RE: updates

Suraj,

In our meetings re: the ELISA Launch and preparation for the LDT validation, EAH has mentioned that this will be the only priority of the entire ELISA team moving forward.
We have 61 assays to validate on the 3.x and 27 on the Siemens Advia.
Unless priorities shift we will stay on course to focus on the above effort.
FYI.

Thanks,

Sharada

=====

PRIVILEGED AND CONFIDENTIAL COMMUNICATION

IMPORTANT – This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which they are addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Theranos, Inc., 1601 S. California Ave, Palo Alto, CA 94304
650-838-9292 www.theranos.com

=====

From: Suraj Saksena
Sent: Tuesday, August 20, 2013 9:51 PM
To: Daniel Edlin
Cc: Sharada Sivaraman; Surekha Gangakhedkar
Subject: RE: updates

Hi Dan,

We have obtained hybridomas that produce antibodies specific for human IL8, IL10, IL1beta and TNFalpha. Our premise being that the high sequence identity amongst the human and pig interleukins would mean that antibodies specific for human interleukins may cross react with porcine interleukins.

In a meeting with Sharada, it was agreed that my group would be responsible for initial characterization of these antibodies (i.e. make sure that they bind the human interleukin as expected), while the ELISA group screens commercially available antibodies (specific for porcine interleukins) to identify capture-detect pairs for a sandwich ELISA format. The ELISA group would then pass on detection antibodies identified by them to see if they form a sandwich pair with the in-house antibody.

- We have already purified antibodies specific for human IL8. Dose response experiments have been conducted and the data

has been sent to Sharada/Surekha. We are waiting for feedback before we proceed to further characterization (i.e. cross reactivity).

- We have purified antibodies specific for human IL1beta and are conducting the dose response experiments. Request for a different detection antibody has been sent to Sharada.
- We are in the process of purifying the IL10 antibody.

Thanks,
Suraj

From: Daniel Edlin

Sent: Tuesday, August 20, 2013 10:41 AM

To: Suraj Saksena

Subject: RE: updates

Hi Suraj,

Can you please provide a status update for the porcine binders/assays?

Thanks,
Dan

Suraj Saksena
Senior Scientist
Theranos, Inc.
1601 S. California Ave.
Palo Alto, CA 94304
(650) 470-0324

=====

PRIVILEGED AND CONFIDENTIAL COMMUNICATION

IMPORTANT - This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This Information is intended solely for the use of the individual or entity to which they are addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this mail in error, please contact us immediately and delete all copies. Please note that any views and opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Theranos, Inc. 1601 S. California Ave. Palo Alto, CA 94304, 650-838-9292 www.theranos.com

=====